@article{Freedman2015-bz,
	title = {The economics of reproducibility in preclinical research},
	volume = {13},
	issn = {1544-9173, 1545-7885},
	url = {https://doi.org/10.1371/journal.pbio.1002165},
	doi = {10.1371/journal.pbio.1002165},
	abstract = {Low reproducibility rates within life science research undermine cumulative knowledge production and contribute to both delays and costs of therapeutic drug development. An analysis of past studies indicates that the cumulative (total) prevalence of irreproducible preclinical research exceeds 50\%, resulting in approximately US28,000,000,000 (US28B)/year spent on preclinical research that is not reproducible-in the United States alone. We outline a framework for solutions and a plan for long-term improvements in reproducibility rates that will help to accelerate the discovery of life-saving therapies and cures.},
	language = {English},
	number = {6},
	journal = {PLOS Biology},
	author = {Freedman, Leonard P. and Cockburn, Iain M. and Simcoe, Timothy S.},
	month = jun,
	year = {2015},
	note = {tex.affiliation: Global Biological Standards Institute, Washington, D.C., United States of America. Boston University School of Management, Boston, Massachusetts, United States of America. Boston University School of Management, Boston, Massachusetts, United States of America; Council of Economic Advisers, Washington, D.C., United States of America.
tex.pmc: PMC4461318
tex.pmid: 26057340},
	pages = {e1002165},
}

{"_id":"rHyY2YwMzHeq3u3xa","bibbaseid":"freedman-cockburn-simcoe-theeconomicsofreproducibilityinpreclinicalresearch-2015","authorIDs":[],"author_short":["Freedman, L. P.","Cockburn, I. M.","Simcoe, T. S."],"bibdata":{"bibtype":"article","type":"article","title":"The economics of reproducibility in preclinical research","volume":"13","issn":"1544-9173, 1545-7885","url":"https://doi.org/10.1371/journal.pbio.1002165","doi":"10.1371/journal.pbio.1002165","abstract":"Low reproducibility rates within life science research undermine cumulative knowledge production and contribute to both delays and costs of therapeutic drug development. An analysis of past studies indicates that the cumulative (total) prevalence of irreproducible preclinical research exceeds 50%, resulting in approximately US28,000,000,000 (US28B)/year spent on preclinical research that is not reproducible-in the United States alone. We outline a framework for solutions and a plan for long-term improvements in reproducibility rates that will help to accelerate the discovery of life-saving therapies and cures.","language":"English","number":"6","journal":"PLOS Biology","author":[{"propositions":[],"lastnames":["Freedman"],"firstnames":["Leonard","P."],"suffixes":[]},{"propositions":[],"lastnames":["Cockburn"],"firstnames":["Iain","M."],"suffixes":[]},{"propositions":[],"lastnames":["Simcoe"],"firstnames":["Timothy","S."],"suffixes":[]}],"month":"June","year":"2015","note":"tex.affiliation: Global Biological Standards Institute, Washington, D.C., United States of America. Boston University School of Management, Boston, Massachusetts, United States of America. Boston University School of Management, Boston, Massachusetts, United States of America; Council of Economic Advisers, Washington, D.C., United States of America. tex.pmc: PMC4461318 tex.pmid: 26057340","pages":"e1002165","bibtex":"@article{Freedman2015-bz,\n\ttitle = {The economics of reproducibility in preclinical research},\n\tvolume = {13},\n\tissn = {1544-9173, 1545-7885},\n\turl = {https://doi.org/10.1371/journal.pbio.1002165},\n\tdoi = {10.1371/journal.pbio.1002165},\n\tabstract = {Low reproducibility rates within life science research undermine cumulative knowledge production and contribute to both delays and costs of therapeutic drug development. An analysis of past studies indicates that the cumulative (total) prevalence of irreproducible preclinical research exceeds 50\\%, resulting in approximately US28,000,000,000 (US28B)/year spent on preclinical research that is not reproducible-in the United States alone. We outline a framework for solutions and a plan for long-term improvements in reproducibility rates that will help to accelerate the discovery of life-saving therapies and cures.},\n\tlanguage = {English},\n\tnumber = {6},\n\tjournal = {PLOS Biology},\n\tauthor = {Freedman, Leonard P. and Cockburn, Iain M. and Simcoe, Timothy S.},\n\tmonth = jun,\n\tyear = {2015},\n\tnote = {tex.affiliation: Global Biological Standards Institute, Washington, D.C., United States of America. Boston University School of Management, Boston, Massachusetts, United States of America. Boston University School of Management, Boston, Massachusetts, United States of America; Council of Economic Advisers, Washington, D.C., United States of America.\ntex.pmc: PMC4461318\ntex.pmid: 26057340},\n\tpages = {e1002165},\n}\n\n","author_short":["Freedman, L. P.","Cockburn, I. M.","Simcoe, T. S."],"key":"Freedman2015-bz","id":"Freedman2015-bz","bibbaseid":"freedman-cockburn-simcoe-theeconomicsofreproducibilityinpreclinicalresearch-2015","role":"author","urls":{"Paper":"https://doi.org/10.1371/journal.pbio.1002165"},"metadata":{"authorlinks":{}},"html":""},"bibtype":"article","biburl":"https://api.zotero.org/users/5255715/collections/8VSDT6LK/items?key=MmxwvnBddD36jsH7fYjmLlnU&format=bibtex&limit=100","creationDate":"2020-03-11T17:05:50.177Z","downloads":0,"keywords":[],"search_terms":["economics","reproducibility","preclinical","research","freedman","cockburn","simcoe"],"title":"The economics of reproducibility in preclinical research","year":2015,"dataSources":["GSdyza34Yogv8tQFT","KH7thnXN2aoT9q4Pu"]}